Elevated pontine and putamenal gaba levels in mild-moderate parkinson disease detected by 7 tesla proton mrs

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Emir, Uzay E ^a   Tuite, Paul J ^b   Öz, Gülin ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PROTON;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GABAERGIC TRANSMISSION; HUMAN; IDIOPATHIC DISEASE; IN VIVO STUDY; MALE; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PONS; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; SUBSTANTIA NIGRA; UPREGULATION; CASE CONTROL STUDY; DISEASE COURSE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

RODENTIA;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PONS; PROTONS; PUTAMEN;

EID: 84856258883     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030918     Document Type: Article

References (57)

1. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16: 653-661.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
3. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, et al. (1990) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27: 373-385.
4. Zarow C, Lyness SA, Mortimer JA, Chui HC, (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341.
5. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ, (2011) Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal (18)F-dopa PET study. Neuroimage 56: 1463-1468.
6. Pavese N, Moore RY, Scherfler C, Khan NL, Hotton G, et al. (2010) In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol 222: 120-124.
7. Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, et al. (2009) Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PLoS One 4: e8247.
8. Baudrexel S, Nurnberger L, Rub U, Seifried C, Klein JC, et al. (2010) Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 51: 512-520.
9. Martin WR, (2001) Magnetic resonance imaging and spectroscopy in Parkinson's disease. Adv Neurol 86: 197-203.
10. Öz G, Terpstra M, Tkáč I, Aia P, Lowary J, et al. (2006) Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 55: 296-301.
11. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, et al. (2002) Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 17: 917-927.
12. Watanabe H, Fukatsu H, Katsuno M, Sugiura M, Hamada K, et al. (2004) Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 75: 103-109.
13. Henchcliffe C, Shungu DC, Mao X, Huang C, Nirenberg MJ, et al. (2008) Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Annals of the New York Academy of Sciences 1147: 206-220.
14. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, et al. (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132: 3285-3297.
15. Kickler N, Krack P, Fraix V, Lebas JF, Lamalle L, et al. (2007) Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR Biomed 20: 757-762.
16. Chassain C, Bielicki G, Durand E, Lolignier S, Essafi F, et al. (2008) Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse. J Neurochem 105: 874-882.
17. Chassain C, Bielicki G, Keller C, Renou JP, Durif F, (2010) Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. NMR Biomed 23: 547-553.
18. Tkáč I, Öz G, Adriany G, Uǧurbil K, Gruetter R, (2009) In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 62: 868-879.
19. Tkáč I, Andersen P, Adriany G, Merkle H, Uǧurbil K, et al. (2001) In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med 46: 451-456.
20. van den Bogaard SJ, Dumas EM, Teeuwisse WM, Kan HE, Webb A, et al. (2011) Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J Neurol doi:10.1007/s00415-00011-06099-00415.
21. Emir UE, Auerbach EJ, Van De Moortele PF, Marjanska M, Uǧurbil K, et al. (2011) Regional neurochemical profiles in the human brain measured by (1) H MRS at 7 T using local B(1) shimming. NMR Biomed doi:10.1002/nbm.1727.
22. Adriany G, Van de Moortele PF, Ritter J, Moeller S, Auerbach EJ, et al. (2008) A geometrically adjustable 16-channel transmit/receive transmission line array for improved RF efficiency and parallel imaging performance at 7 Tesla. Magn Reson Med 59: 590-597.
23. Tkáč I, Starcuk Z, Choi IY, Gruetter R, (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41: 649-656.
24. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, et al. (2006) Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 21: 958-963.
25. Kish SJ, Rajput A, Gilbert J, Rozdilsky B, Chang LJ, et al. (1986) Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol 20: 26-31.
26. Kish SJ, Shannak K, Hornykiewicz O, (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
27. Natt O, Bezkorovaynyy V, Michaelis T, Frahm J, (2005) Use of phased array coils for a determination of absolute metabolite concentrations. Magn Reson Med 53: 3-8.
28. Jenkinson M, Bannister P, Brady M, Smith S, (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17: 825-841.
29. Lancaster JL, Tordesillas-Gutierrez D, Martinez M, Salinas F, Evans A, et al. (2007) Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template. Hum Brain Mapp 28: 1194-1205.
30. Naidich TP, Duvernoy HM, Delman BN, Sorensen AG, Kollias SS, et al. (2009) Gross Sectional Anatomy and 3T MRI Correlations in Axial, Coronal and Sagittal Planes Duvernoy's Atlas of the Human Brain Stem and Cerebellum. Springer Vienna pp. 561-835.
31. Naidich TP, Duvernoy HM, Delman BN, Sorensen AG, Kollias SS, et al. (2009) Internal Architecture of the Brain Stem with Key Axial Section Duvernoy's Atlas of the Human Brain Stem and Cerebellum. Springer Vienna pp. 53-93.
32. Keren NI, Lozar CT, Harris KC, Morgan PS, Eckert MA, (2009) In vivo mapping of the human locus coeruleus. Neuroimage 47: 1261-1267.
33. Provencher SW, (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
34. Provencher SW, (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14: 260-264.
35. Govindaraju V, Young K, Maudsley AA, (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13: 129-153.
36. Tkáč I, (2008) Refinement of simulated basis set for LCModel analysis. Proceedings 16th Scientific Meeting, International Society for Magnetic Resonance in Medicine Toronto pp. 1624.
37. Behar KL, Rothman DL, Spencer DD, Petroff OA, (1994) Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med 32: 294-302.
38. Randall LO, (1938) Chemical topography of the brain. J Biol Chem 124: 481-488.
39. Gelman N, Ewing JR, Gorell JM, Spickler EM, Solomon EG, (2001) Interregional variation of longitudinal relaxation rates in human brain at 3.0 T: relation to estimated iron and water contents. Magn Reson Med 45: 71-79.
40. Provencher SW, (2001) LCModel & LCMgui User's Manual.
41. Braak H, Rub U, Del Tredici K, (2006) Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 248: 255-258.
42. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, et al. (2006) Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 17: 1215-1218.
43. Clark JB, (1998) N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20: 271-276.
44. Moore RY, Whone AL, Brooks DJ, (2008) Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol Dis 29: 381-390.
45. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ, (2003) Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60: 601-605.
46. Gervasoni D, Darracq L, Fort P, Souliere F, Chouvet G, et al. (1998) Electrophysiological evidence that noradrenergic neurons of the rat locus coeruleus are tonically inhibited by GABA during sleep. Eur J Neurosci 10: 964-970.
47. Gervasoni D, Peyron C, Rampon C, Barbagli B, Chouvet G, et al. (2000) Role and origin of the GABAergic innervation of dorsal raphe serotonergic neurons. J Neurosci 20: 4217-4225.
48. Perry TL, Javoy-Agid F, Agid Y, Fibiger HC, (1983) Striatal GABAergic neuronal activity is not reduced in Parkinson's disease. J Neurochem 40: 1120-1123.
49. Laprade N, Soghomonian JJ, (1997) Glutamate decarboxylase (GAD65) gene expression is increased by dopamine receptor agonists in a subpopulation of rat striatal neurons. Brain Res Mol Brain Res 48: 333-345.
50. Soghomonian JJ, Laprade N, (1997) Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of Parkinsonian monkeys. Synapse 27: 122-132.
51. Dydak U, Jiang YM, Long LL, Zhu H, Chen J, et al. (2011) In vivo measurement of brain GABA concentrations by magnetic resonance spectroscopy in smelters occupationally exposed to manganese. Environ Health Perspect 119: 219-224.
52. Tanaka Y, Niijima K, Mizuno Y, Yoshida M, (1986) Changes in gamma-aminobutyrate, glutamate, aspartate, glycine, and taurine contents in the striatum after unilateral nigrostriatal lesions in rats. Exp Neurol 91: 259-268.
53. Whone AL, Moore RY, Piccini PP, Brooks DJ, (2003) Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 53: 206-213.
54. Edden RA, Barker PB, (2007) Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation. Magn Reson Med 58: 1276-1282.
55. Kaiser LG, Young K, Meyerhoff DJ, Mueller SG, Matson GB, (2008) A detailed analysis of localized J-difference GABA editing: theoretical and experimental study at 4 T. NMR Biomed 21: 22-32.
56. Terpstra M, Uǧurbil K, Gruetter R, (2002) Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla. Magn Reson Med 47: 1009-1012.
57. Martin WR, Wieler M, Gee M, (2008) Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70: 1411-1417.